OTC · Health care

RetinalGenix Technologies Inc. (RTGN)

It posted a net loss of $2.1M. At June 30, 2026 it held $27.2K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch RTGN in 60 seconds

Price

$3.99

0.00% on the day · September 25, 2026

52-week range $3.20 to $4.01

Market cap

$75.2M

What RetinalGenix Technologies Inc. does

RetinalGenix Technologies Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker RTGN.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	n/a	-$2.4M	-$0.13	n/a
2024	n/a	n/a	-$4.3M	-$0.24	n/a
2023	n/a	n/a	-$2.1M	-$0.12	n/a
2022	n/a	n/a	-$3.9M	-$0.25	n/a
2021	n/a	n/a	-$2.2M	-$0.05	n/a
2021	n/a	n/a	-$2.1M	-$0.05	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What RetinalGenix Technologies Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.02 versus -$0.03.
July 15, 2026
Auditor change 8-K
May 20, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.03 versus -$0.03.
May 15, 2026
Late quarterly report notice NT 10-Q
April 15, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS -$0.13 versus -$0.24.
March 30, 2026
Late annual report notice NT 10-K
March 26, 2026
Executive or director change 8-K
November 14, 2025
Quarterly report 10-Q · period to September 30, 2025Diluted EPS -$0.03 versus -$0.04.
August 20, 2025
Quarterly report (amended) 10-Q/A · period to June 30, 2025Diluted EPS was -$0.03.
August 19, 2025
Quarterly report 10-Q · period to June 30, 2025Diluted EPS was -$0.03.

Recent insider filings (Forms 3, 4 and 144): 8, the latest on June 10, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about RTGN

What does RetinalGenix Technologies Inc. do?

RetinalGenix Technologies Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker RTGN.

Is RetinalGenix Technologies Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $2.1M.

When did RetinalGenix Technologies Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Becton Dickinson & Co

BSX

Boston Scientific Corp

BAX

Baxter International Inc

Compare RTGN with

Compare RTGN with any company

Follow RTGN

Get an email when RetinalGenix Technologies Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow RTGN: get an email when it files

Where the numbers come from

Financial figures are the values RetinalGenix Technologies Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.